Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0EP0C
|
|||
Former ID |
DAP000297
|
|||
Drug Name |
Spironolactone
|
|||
Synonyms |
Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50.0; ICD-9: 428] | Approved | [1], [2] | |
Therapeutic Class |
Diuretics
|
|||
Company |
Pfizer Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H32O4S
|
|||
Canonical SMILES |
CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C
|
|||
InChI |
1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
|
|||
InChIKey |
LXMSZDCAJNLERA-ZHYRCANASA-N
|
|||
CAS Number |
CAS 52-01-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9518, 431586, 3138746, 6436731, 7847509, 7890527, 7980649, 8153601, 11466156, 11467276, 11485851, 12157539, 14782265, 14855731, 22395181, 24277736, 26717209, 26757816, 29204585, 29224866, 46508525, 47193741, 47277003, 47500920, 48020409, 48244799, 49699055, 50019597, 50111676, 50928797, 53788778, 56314087, 56320673, 56320674, 56352940, 56462986, 57288839, 57322990, 83591809, 85787487, 87575785, 92125142, 92309277, 92711407, 93167089, 93576647, 93619777, 103469419, 103913949, 104097735
|
|||
ChEBI ID |
CHEBI:9241
|
|||
ADReCS Drug ID | BADD_D02066 | |||
SuperDrug ATC ID |
C03DA01
|
|||
SuperDrug CAS ID |
cas=000052017
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Metabolism of Drug Affected by Studied Microbe(s) | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
Studied Microbe: Gut microbiota unspecific | [3] | |||
Metabolic Reaction | Thioester hydrolysis | |||
Experimental Method | High-throughput screening | |||
Description | Spironolactone can be metabolized by gut microbiota through thioester hydrolysis. |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Mineralocorticoid receptor (MR) | Target Info | Modulator | [4] |
KEGG Pathway | Aldosterone-regulated sodium reabsorption | |||
Pathwhiz Pathway | Kidney Function | |||
WikiPathways | ACE Inhibitor Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2875). | |||
REF 2 | Emerging drugs for complications of end-stage liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):159-74. | |||
REF 3 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.